Idarucizumab for dabigatran reversal

New England Journal of Medicine

Volumn 373, Issue 6, 2015, Pages 511-520

  Pollack, Charles V ^a   Reilly, Paul A ^b   Eikelboom, John ^c   Glund, Stephan ^e   Verhamme, Peter ^h   Bernstein, Richard A ⁱ   Dubiel, Robert ^b   Huisman, Menno V ^j,k   Hylek, Elaine M ^l   Kamphuisen, Pieter W ^l   Kreuzer, Jörg ^f   Levy, Jerrold H ^m   Sellke, Frank W ⁿ   Stangier, Joachim ^e   Steiner, Thorsten ^g   Wang, Bushi ^b   Kam, Chak Wah ^o   Weitz, Jeffrey I ^c,d  

^a THOMAS JEFFERSON UNIVERSITY   (United States)

^b BOEHRINGER INGELHEIM PHARMACEUTICALS INC   (United States)

^c MCMASTER UNIVERSITY   (Canada)

^d MCMASTER UNIVERSITY   (Canada)

^e BOEHRINGER INGELHEIM PHARMA GMBH AND CO KG   (Germany)

^f UNIVERSITY HOSPITAL FRANKFURT   (Germany)

^g UNIVERSITY HOSPITAL HEIDELBERG   (Germany)

^h UNIVERSITY OF LEUVEN   (Belgium)

ⁱ NORTHWESTERN UNIVERSITY   (United States)

^j LEIDEN UNIVERSITY MEDICAL CENTER   (Netherlands)

^k UNIVERSITY MEDICAL CENTER GRONINGEN   (Netherlands)

^l BOSTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

^m DUKE UNIVERSITY MEDICAL CENTER   (United States)

ⁿ RHODE ISLAND HOSPITAL   (United States)

^o TUEN MUN HOSPITAL   (Hong Kong)

more..

Author keywords

[No Author keywords available]

Indexed keywords

DABIGATRAN; ECARIN; IDARUCIZUMAB; ANTICOAGULANT AGENT; BENZIMIDAZOLE DERIVATIVE; BETA ALANINE; MONOCLONAL ANTIBODY;

ADULT; AGED; ANTICOAGULATION; ARTICLE; ATRIAL FIBRILLATION; BLOOD CLOTTING TIME; BRAIN HEMORRHAGE; BRAIN ISCHEMIA; CANCER GROWTH; CAUSE OF DEATH; CEREBROVASCULAR ACCIDENT; COHORT ANALYSIS; CONGESTIVE HEART FAILURE; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DEEP VEIN THROMBOSIS; DELIRIUM; DOSE TIME EFFECT RELATION; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG EFFICACY; DRUG SAFETY; FEMALE; GASTROINTESTINAL HEMORRHAGE; GENERAL CONDITION DETERIORATION; HEART ARREST; HEART ATRIUM THROMBOSIS; HEART RIGHT VENTRICLE FAILURE; HEMODYNAMICS; HUMAN; LUNG EDEMA; LUNG EMBOLISM; MAJOR CLINICAL STUDY; MALE; MIDDLE AGED; MULTICENTER STUDY; MULTIPLE ORGAN FAILURE; NON ST SEGMENT ELEVATION MYOCARDIAL INFARCTION; PARKINSON DISEASE; PHARMACODYNAMICS; PNEUMONIA; PRIORITY JOURNAL; PROSPECTIVE STUDY; RESPIRATORY FAILURE; SEPSIS; SEPTIC SHOCK; SHOCK; SURGICAL INFECTION; THROMBIN TIME; THROMBOSIS; VENOUS THROMBOEMBOLISM; VERY ELDERLY; ANALOGS AND DERIVATIVES; ANTAGONISTS AND INHIBITORS; BLOOD; BLOOD CLOTTING; CHEMICALLY INDUCED; CLINICAL TRIAL; DRUG EFFECTS; HEMORRHAGE; INTRAVENOUS DRUG ADMINISTRATION;

AGED; AGED, 80 AND OVER; ANTIBODIES, MONOCLONAL, HUMANIZED; ANTICOAGULANTS; BENZIMIDAZOLES; BETA-ALANINE; BLOOD COAGULATION; FEMALE; HEMORRHAGE; HUMANS; INFUSIONS, INTRAVENOUS; MALE; MIDDLE AGED; PROSPECTIVE STUDIES; THROMBOSIS;

EID: 84938836381     PISSN: 00284793     EISSN: 15334406     Source Type: Journal    
DOI: 10.1056/NEJMoa1502000     Document Type: Article

References (14)

1. Connolly SJ, Ezekowitz MD, Yusuf S, et al. Dabigatran versus warfarin in patients with atrial fibrillation. N Engl J Med 2009; 361: 1139-51.
2. Yeh CH, Gross PL, Weitz JI. Evolving use of new oral anticoagulants for treatment of venous thromboembolism. Blood 2014; 124: 1020-8.
3. Graham DJ, Reichman ME, Wernecke M, et al. Cardiovascular, bleeding, and mortality risks in elderly Medicare patients treated with dabigatran or warfarin for nonvalvular atrial fibrillation. Circulation 2015; 131: 157-64.
4. van Ryn J, Stangier J, Haertter S, et al. Dabigatran etexilate - a novel, reversible, oral direct thrombin inhibitor: interpretation of coagulation assays and reversal of anticoagulant activity. Thromb Haemost 2010; 103: 1116-27.
5. Schiele F, van Ryn J, Canada K, et al. A specific antidote for dabigatran: functional and structural characterization. Blood 2013; 121: 3554-62.
6. Glund S, Moschetti V, Norris S, et al. A randomised study in healthy volunteers to investigate the safety, tolerability and pharmacokinetics of idarucizumab, a specific antidote to dabigatran. Thromb Haemost 2015; 113: 943-51.
7. Glund S, Stangier J, Schmohl M, et al. Idarucizumab, a specific antidote for dabigatran: immediate, complete and sustained reversal of dabigatran induced anticoagulation in elderly and renally impaired subjects. Blood 2014; 124: 344. abstract.
8. Glund S, Stangier J, Schmohl M, et al. Safety, tolerability, and efficacy of idarucizumab for the reversal of the anticoagulant effect of dabigatran in healthy male volunteers: a randomised, placebo-controlled, double-blind phase 1 trial. Lancet 2015 June 15 (Epub ahead of print).
9. Reilly PA, Lehr T, Haertter S, et al. The effect of dabigatran plasma concentrations and patient characteristics on the frequency of ischemic stroke and major bleeding in atrial fibrillation patients: the RE-LY Trial (Randomized Evaluation of Long-Term Anticoagulation Therapy). J Am Coll Cardiol 2014; 63: 321-8.
10. Schulman S, Angers U, Bergqvist D, Eriksson B, Lassen MR, Fisher W. Definition of major bleeding in clinical investigations of antihemostatic medicinal products in surgical patients. J Thromb Haemost 2010; 8: 202-4.
11. The GUSTO Investigators. An international randomized trial comparing four thrombolytic strategies for acute myocardial infarction. N Engl J Med 1993; 329: 673-82.
12. Wilson JT, Hareendran A, Grant M, et al. Improving the assessment of outcomes in stroke: use of a structured interview to assign grades on the modified Rankin Scale. Stroke 2002; 33: 2243-6.
13. Dennis M, Mead G, Doubal F, Graham C. Determining the modified Rankin score after stroke by postal and telephone questionnaires. Stroke 2012; 43: 851-3.
14. Sarode R, Milling TJ Jr, Refaai MA, et al. Efficacy and safety of a 4-factor prothrombin complex concentrate in patients on vitamin K antagonists presenting with major bleeding: a randomized, plasmacontrolled, phase IIIb study. Circulation 2013; 128: 1234-43.